The government’s top vaccine official working under Health Secretary Robert F. Kennedy Jr. recently restricted the approval ...

Pfizer (PFE) closed at $25.32 in the latest trading session, marking a +1.12% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.48% for the day. Elsewhere, the Dow ...

Pfizer exec Philip Dormitzer amid claims the COVID-19 vaccine announcement was delayed to avoid influencing the 2020 election ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

We view Pfizer’s dividends and share repurchase levels as reasonable. Pfizer has generally targeted close to a 50% payout in dividends as a percentage of normalized earnings, which seems about right ...

The House Judiciary Committee subpoenaed a former Pfizer executive who allegedly claimed senior members of the company ...

A former Pfizer scientist was subpoenaed Monday by House Republicans over allegations that there was a conspiracy among ...

In a pivotal randomised controlled trial, the BNT162b2 mRNA vaccine (tozinameran, Pfizer–BioNTech) showed 95% or greater efficacy against symptomatic and severe COVID-19 disease due to SARS-CoV-2. 1 ...

The lawmakers accuse Pfizer, Merck, J&J, AbbVie and Amgen of paying little to nothing in federal taxes despite generating billions of dollars annually.

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.